TY - JOUR
T1 - JAK2V617F allele burden is associated with transformation to myelofibrosis
AU - Koren-Michowitz, Maya
AU - Landman, Joseph
AU - Cohen, Yoram
AU - Rahimi-Levene, Naomi
AU - Salomon, Ophira
AU - Michael, Maria
AU - Amariglio, Ninette
AU - Nagler, Arnon
PY - 2012/11
Y1 - 2012/11
N2 - The JAK2V617F mutation has emerged in recent years as a diagnostic as well as treatment target in patients with polycythemia vera (PV). We analyzed JAK2V617F allele burden (JAK2V617F) in a Jewish population with PV. Results were correlated with disease symptoms and complications. Median JAK2V617F was 48% and 54% in patients of Ashkenazi and non-Ashkenazi origin, respectively (p = 0.75). Higher JAK2V617F was seen in patients with imaging-proven splenomegaly (p = 0.01). A correlation between JAK2V617F and the weekly hydoxyurea dose needed for disease control was found (p = 0.043). In addition, a trend for higher allele burden in patients with longer disease duration (p = 0.064) and those treated with cytoreductive drugs other than hydroxyurea (p = 0.056) was noted. Higher JAK2V617F was seen in patients with transformation to myelofibosis (p = 0.0001), but not in patients with vascular complications. JAK2V617F may assist in prognostic stratification of patients with PV.
AB - The JAK2V617F mutation has emerged in recent years as a diagnostic as well as treatment target in patients with polycythemia vera (PV). We analyzed JAK2V617F allele burden (JAK2V617F) in a Jewish population with PV. Results were correlated with disease symptoms and complications. Median JAK2V617F was 48% and 54% in patients of Ashkenazi and non-Ashkenazi origin, respectively (p = 0.75). Higher JAK2V617F was seen in patients with imaging-proven splenomegaly (p = 0.01). A correlation between JAK2V617F and the weekly hydoxyurea dose needed for disease control was found (p = 0.043). In addition, a trend for higher allele burden in patients with longer disease duration (p = 0.064) and those treated with cytoreductive drugs other than hydroxyurea (p = 0.056) was noted. Higher JAK2V617F was seen in patients with transformation to myelofibosis (p = 0.0001), but not in patients with vascular complications. JAK2V617F may assist in prognostic stratification of patients with PV.
KW - Ashkenazi
KW - JAK2V617F
KW - neoplasm
KW - polycythemia vera
KW - PPVMF
UR - http://www.scopus.com/inward/record.url?scp=84867155062&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.682308
DO - 10.3109/10428194.2012.682308
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22524513
AN - SCOPUS:84867155062
SN - 1042-8194
VL - 53
SP - 2210
EP - 2213
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -